David F. Jarrard, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Urology|
Professional Certifications and Education
Urologic Oncology, Johns Hopkins Hospital, Baltimore, MD
University of Chicago Medical Center, Chicago, IL
University of Chicago Medical Center, Chicago, IL
University of Virginia School of Medicine, Charlottesville, VA, 1989
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF .
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One. 2017;12(2):e0172048
[PubMed ID: 28234906]
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ .
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 2017 Feb;100:139-144
[PubMed ID: 27667156]
Heninger E Krueger TE Thiede SM Sperger JM Byers BL Kircher MR Kosoff D Yang B Jarrard DF McNeel DG Lang JM .
Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016 Dec 20;7(51):84359-84374
[PubMed ID: 27769045]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ .
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology. 2016 Oct;96:93-98
[PubMed ID: 27339026]
Jarrard D Konety B Huang W Downs T Kolesar J Kim KM Havighurst T Slaton J House MG Parnes HL Bailey HH .
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol. 2016;4(2):17-27
[PubMed ID: 27766277]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ .
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep;118(3):399-407
[PubMed ID: 26589741]
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH .
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev. 2016 Jul;25(4):312-20
[PubMed ID: 26313229]
Jarrard DF Huang W .
The New Age of Molecular Taxonomy Approaches. Eur Urol. 2016 Apr;69(4):561-2
[PubMed ID: 26626616]
Kelcz F Jarrard DF .
Prostate cancer: The applicability of textural analysis of MRI for grading. Nat Rev Urol. 2016 Apr;13(4):185-6
[PubMed ID: 26878802]
Blute ML Jr Rushmer TJ Shi F Fuller BJ Abel EJ Jarrard DF Downs TM .
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2015 Nov;194(5):1214-9
[PubMed ID: 26173101]
Abel EJ Heckman JE Hinshaw L Best S Lubner M Jarrard DF Downs TM Nakada SY Lee FT Jr Huang W Ziemlewicz T .
Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. J Urol. 2015 Oct;194(4):886-91
[PubMed ID: 25837535]
Sweeney CJ Chen YH Carducci M Liu G Jarrard DF Eisenberger M Wong YN Hahn N Kohli M Cooney MM Dreicer R Vogelzang NJ Picus J Shevrin D Hussain M Garcia JA DiPaola RS .
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46
[PubMed ID: 26244877]
Blute ML Jr Abel EJ Downs TM Kelcz F Jarrard DF .
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015 Aug;12(8):435-44
[PubMed ID: 26171803]
Yang B Damaschke N Yao T McCormick J Wagner J Jarrard D .
Pyrosequencing for accurate imprinted allele expression analysis. J Cell Biochem. 2015 Jul;116(7):1165-70
[PubMed ID: 25581900]
Wagner J Damaschke N Yang B Truong M Guenther C McCormick J Huang W Jarrard D .
Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. PLoS One. 2015;10(4):e0124366
[PubMed ID: 25876105]
Blute ML Jr Damaschke NA Jarrard DF .
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2015 Jan;25(1):83-8
[PubMed ID: 25405932]
Keil KP Abler LL Laporta J Altmann HM Yang B Jarrard DF Hernandez LL Vezina CM .
Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. Dev Biol. 2014 Dec 15;396(2):237-45
[PubMed ID: 25446526]
Jarrard DF Blute ML Jr Ritter MA .
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol. 2014 Dec 10;32(35):3926-9
[PubMed ID: 25332250]
Abel EJ Linder BJ Bauman TM Bauer RM Thompson RH Thapa P Devon ON Tarrell RF Frank I Jarrard DF Downs TM Boorjian SA .
Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014 Dec;66(6):1139-47
[PubMed ID: 25194909]
Damaschke NA Yang B Blute ML Jr Lin CP Huang W Jarrard DF .
Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia. 2014 Dec;16(12):1018-27
[PubMed ID: 25499215]